N/A
Manufactured by GlaxoSmithKline LLC
19,705 FDA adverse event reports analyzed
Last updated: 2026-04-14
SALMETEROL XINAFOATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by GlaxoSmithKline LLC. The most commonly reported adverse reactions for SALMETEROL XINAFOATE include DYSPNOEA, DRUG INEFFECTIVE, ASTHMA, COUGH, HEADACHE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for SALMETEROL XINAFOATE.
Out of 8,521 classified reports for SALMETEROL XINAFOATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 19,705 FDA FAERS reports that mention SALMETEROL XINAFOATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DYSPNOEA, DRUG INEFFECTIVE, ASTHMA, COUGH, HEADACHE, PNEUMONIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list GlaxoSmithKline LLC in connection with SALMETEROL XINAFOATE. Always verify the specific product and NDC with your pharmacist.